NASDAQ
ACAD
Last Price
US $25.49
KEY FIGURES
MKT CAP
$4.4B
EPS
TTM
$2.20
PEG
TTM
0.19x
P/E
TTM
11.57x
P/S
TTM
3.97x
YIELD
0.00%
GROWTH
Revenue Y/Y
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
ACADIA Pharmaceuticals Inc. cash flow to debt ratio of 210.47% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Financial risk - Healthy cash flow growth.
ACADIA Pharmaceuticals Inc.'s free cash flow has decreased -33.11% from $157.20M last year to $105.15M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
ACADIA Pharmaceuticals Inc.'s debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
ACADIA Pharmaceuticals Inc.'s debt has decreased relative to shareholder equity from 0.07 last year to 0.04 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
ACADIA Pharmaceuticals Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
ACADIA Pharmaceuticals Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial stability - Profit margin growth.
ACADIA Pharmaceuticals Inc.'s profit margin has increased (45.07%) in the last year from 23.64% to 34.30%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
ACADIA Pharmaceuticals Inc.'s short-term assets of $1.06G exceed its short-term liabilities of $277.11M
Increasing performance - ROA.
ACADIA Pharmaceuticals Inc.'s return on assets of 23.40% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
ACADIA Pharmaceuticals Inc.'s return on equity of 35.65%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
ACADIA Pharmaceuticals Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
ACADIA Pharmaceuticals Inc. had positive net income in only 2.00 out of 5 years, indicating unstable earnings
Increasing performance - Free cash flow.
ACADIA Pharmaceuticals Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
ACADIA Pharmaceuticals Inc. has a free cash flow yield of 2.41%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Increasing performance - Healthy earnings growth.
ACADIA Pharmaceuticals Inc.'s yearly earnings has increased 72.66% since last year from $226.45M to $391.00M, signaling increasing performance
Increasing performance - Healthy revenue growth.
ACADIA Pharmaceuticals Inc.'s yearly revenue has increased 11.87% since last year from $957.80M to $1.07G, signaling increasing performance
Increasing performance - ROIC.
ROIC 6.17% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.
Increasing performance - 3-year revenue CAGR.
ACADIA Pharmaceuticals Inc.'s 3-year revenue CAGR of 27.48% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
ACADIA Pharmaceuticals Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
ACADIA Pharmaceuticals Inc. had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
ACADIA Pharmaceuticals Inc. has insufficient data to evaluate this check.
Undervalued - Earnings yield.
ACADIA Pharmaceuticals Inc. has an earnings yield of 8.64%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
ACADIA Pharmaceuticals Inc. is overvalued relative to its fair value price of 6.44 based on EBITDA multiple model
Overvalued - EV/EBITDA.
ACADIA Pharmaceuticals Inc. has an EV/EBITDA ratio of 28.14x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings
Undervalued - PEG ratio value.
ACADIA Pharmaceuticals Inc. has a PEG-ratio under 1 which is considered undervalued
Undervalued - P/B ratio.
ACADIA Pharmaceuticals Inc. has a price-to-book ratio of 3.48x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
ACADIA Pharmaceuticals Inc. has a price-to-sales ratio of 3.97x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
35.65%
Return on equity
ROIC: 6.17%
Valuation History
11.8X
Price to Earnings
EV/EBITDA: 33.5X
Cash flow
Profit margin
19.39%
(FY vs FY)
EBITDA Y/Y
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $25.49
—
Default assumptions
EBITDA Multiple
Fair Value
Market $25.49
-74.74%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.